Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
Tazemetostat is a methyltransferase inhibitor. Tazemetostat hydrobromide has the following chemical name: [1,1’-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5- [ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4’-(4-morpholinylmethyl)-, hydrobromide (1:1). The molecular formula of tazemetostat hydrobromide is C34H44N4O4•HBr. Tazemetostat hydrobromide has a molecular weight of 653.66 g/mol and the following structural formula:
 |
Tazemetostat hydrobromide is a white to off-white solid that is slightly soluble in water and has pKa values of 5.26, 6.88, and 12.62. A saturated aqueous solution of tazemetostat hydrobromide has a pH of approximately 5 at ambient conditions.
TAZVERIK (tazemetostat) tablets for oral use contain 200 mg tazemetostat, equivalent to 228 mg tazemetostat hydrobromide.
Each tablet is film-coated and contains the following inactive ingredients in the tablet core: hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, and sodium starch glycolate. The film-coat contains hypromellose, polyethylene glycol, red iron oxide, talc, and titanium dioxide.
TAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
These indications are approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies]. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Select patients with R/R FL for treatment with TAZVERIK based on the presence of EZH2 mutation of codons Y646, A682, or A692 in tumor specimens [see Clinical Studies]. Information on FDA-approved tests for the detection of EZH2 mutation in relapsed or refractory follicular lymphoma is available at: https://www.fda.gov/CompanionDiagnostics.
The recommended dosage of TAZVERIK is 800 mg orally twice daily with or without food until disease progression or unacceptable toxicity.
Swallow tablets whole. Do not cut, crush, or chew tablets.
Do not take an additional dose if a dose is missed or vomiting occurs after TAZVERIK, but continue with the next scheduled dose.
Table 1 summarizes the recommended dose reductions, and Table 2 summarizes the recommended dosage modifications of TAZVERIK for adverse reactions.
Table 1: Recommended Dose Reductions of TAZVERIK for Adverse Reactions
| Dose Reduction | Dosage |
| First | 600 mg orally twice daily |
| Second | 400 mg orally twice daily* |
| *Permanently discontinue TAZVERIK in patients who are unable to tolerate 400 mg orally twice daily. | |
Table 2: Recommended Dosage Modifications of TAZVERIK for Adverse Reactions
| Adverse Reaction | Severity | Dosage Modification |
| Neutropenia [see ADVERSE REACTIONS] | Neutrophil count less than 1 x 109/L |
|
| Thrombocytopenia [see ADVERSE REACTIONS] | Platelet count less than 50 x 109/L |
|
| Anemia [see ADVERSE REACTIONS] | Hemoglobin less than 8 g/dL |
|
| Other adverse reactions [see ADVERSE REACTIONS] | Grade 3 |
|
| Grade 4 |
|
Avoid coadministration of TAZVERIK with strong or moderate CYP3A inhibitors. If coadministration with a strong or moderate CYP3A inhibitor cannot be avoided, reduce the TAZVERIK dose as shown in Table 3 below. After discontinuation of the strong or moderate CYP3A inhibitor for 3 elimination half-lives, resume the TAZVERIK dose that was taken prior to initiating the inhibitor [see DRUG INTERACTIONS, CLINICAL PHARMACOLOGY].
Table 3: Recommended Dose Reductions of TAZVERIK for Strong or Moderate CYP3A Inhibitors
| Current Dosage | Adjusted Dosage |
| 800 mg orally twice daily | 400 mg orally twice daily |
| 600 mg orally twice daily | 400 mg for first dose and 200 mg for second dose |
| 400 mg orally twice daily | 200 mg orally twice daily |
Tablets: 200 mg film-coated, red, round, biconvex shape and debossed with “EZM 200” on one side and plain on the other.
TAZVERIK 200 mg film-coated tablets are red, round, biconvex shape and debossed with “EZM 200” on one side and plain on the other. TAZVERIK is available in:
Bottles of 240 tablets with a desiccant; NDC 72607-100-00
Do not store above 30°C(86°F).
Manufactured for: Epizyme, Inc. An Ipsen Company One Main St. Cambridge, MA 02142. Revised: Aug 2024
The following clinically significant adverse reactions are described elsewhere in labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of TAZVERIK was evaluated in a cohort (Cohort 5) of Study EZH-202 that enrolled patients with epithelioid sarcoma [see Clinical Studies]. Patients received TAZVERIK 800 mg orally twice daily (n=62). Among patients who received TAZVERIK, 44% were exposed for 6 months or longer and 24% were exposed for greater than one year.
Serious adverse reactions occurred in 37% of patients who received TAZVERIK. Serious adverse reactions in ≥3% of patients who received TAZVERIK were hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress.
One patient (2%) permanently discontinued TAZVERIK due to an adverse reaction of altered mood.
Dosage interruptions due to an adverse reaction occurred in 34% of patients who received TAZVERIK. The most frequent adverse reactions requiring dosage interruptions in ≥3% were hemorrhage, increased alanine aminotransferase (ALT), and increased aspartate aminotransferase (AST).
Dose reduction due to an adverse reaction occurred in one (2%) patient who received TAZVERIK; the dose was reduced in this patient for decreased appetite.
The most common adverse reactions (≥20%) were pain, fatigue, nausea, decreased appetite, vomiting, and constipation.
Table 4 presents adverse reactions in patients with epithelioid sarcoma in Cohort 5 of Study EZH-202.
Table 4: Adverse Reactions (≥10%) in Patients with Epithelioid Sarcoma Who Received TAZVERIK in Cohort 5 of Study EZH-202
| Adverse Reaction | TAZVERIK N=62 |
|
| All Grades (%) | Grade 3 or 4 (%) | |
| General | ||
| Paina | 52 | 7 |
| Fatigueb | 47 | 1.6 |
| Gastrointestinal | ||
| Nausea | 36 | 0 |
| Vomiting | 24 | 0 |
| Constipation | 21 | 0 |
| Diarrhea | 16 | 0 |
| Abdominal painc | 13 | 1.6 |
| Metabolism and nutrition | ||
| Decreased appetite | 26 | 4.8 |
| Respiratory, thoracic and mediastinal | ||
| Cough | 18 | 0 |
| Dyspnead | 16 | 4.8 |
| Vascular | ||
| Hemorrhagee | 18 | 4.8 |
| Nervous system | ||
| Headache | 18 | 0 |
| Investigations | ||
| Weight decreased | 16 | 7 |
| a Includes tumor pain, pain in extremity, non-cardiac chest pain, flank pain, back pain, arthralgia, bone pain, cancer pain, musculoskeletal pain, myalgia, neck pain b Includes fatigue and asthenia c Includes abdominal pain, gastrointestinal pain, abdominal pain lower d Includes dyspnea and dyspnea exertional e Includes wound hemorrhage, rectal hemorrhage, pulmonary hemorrhage, hemorrhage intracranial, cerebral hemorrhage, hemoptysis |
||
Table 5 summarizes select laboratory abnormalities in patients with epithelioid sarcoma in Cohort 5 of Study EZH-202.
Table 5: Select Laboratory Abnormalities (≥ 10%) Worsening from Baseline in Patients with Epithelioid Sarcoma Who Received TAZVERIK in Cohort 5 of Study EZH-202
| Laboratory Abnormality | TAZVERIK* | |
| All Grades (%) | Grade 3 or 4 (%) | |
| Hematology | ||
| Decreased hemoglobin | 49 | 15 |
| Decreased lymphocytes | 36 | 13 |
| Decreased white blood cell count | 19 | 0 |
| Chemistry | ||
| Increased triglycerides | 36 | 3.3 |
| Increased glucose | 33 | 1.6 |
| Decreased sodium | 30 | 1.7 |
| Decreased phosphate | 28 | 1.7 |
| Decreased albumin | 23 | 0 |
| Increased alkaline phosphatase | 23 | 1.7 |
| Decreased potassium | 20 | 1.7 |
| Increased aspartate aminotransferase | 18 | 3.5 |
| Decreased calcium | 16 | 0 |
| Decreased glucose | 16 | 0 |
| Increased partial thromboplastin time | 15 | 5 |
| Increased alanine aminotransferase | 14 | 3.4 |
| Increased creatinine | 12 | 0 |
| Increased potassium | 12 | 0 |
| *The denominator used to calculate the rate varied from 39 to 61 based on the number of patients with a baseline value and at least one post-treatment value. | ||
The safety of TAZVERIK was evaluated in two cohorts (Cohorts 4 and 5) of Study E7438-G000-101 that enrolled patients with relapsed or refractory follicular lymphoma [see Clinical Studies]. Patients received TAZVERIK 800 mg orally twice daily (n=99). Among patients who received TAZVERIK, 68% were exposed for 6 months or longer, 39% were exposed for 12 months or longer, and 21% were exposed for 18 months or longer.
The median age was 62 years (range 36 to 87 years), 54% were male, and 95% had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The median number of prior therapies was 3 (range 1 to 11). Patients were required to have a creatinine clearance ≥40 mL/min per the Cockcroft and Gault formula.
Serious adverse reactions occurred in 30% of patients who received TAZVERIK. Serious adverse reactions in ≥2% of patients who received TAZVERIK were general physical health deterioration, abdominal pain, pneumonia, sepsis, and anemia.
Permanent discontinuation due to an adverse reaction occurred in 8% of patients who received TAZVERIK. Adverse reaction resulting in permanent discontinuation in ≥2% of patients was second primary malignancy.
Dosage interruptions due to an adverse reaction occurred in 28% of patients who received TAZVERIK.
Adverse reactions requiring dosage interruptions in ≥3% of patients were thrombocytopenia and fatigue.
Dose reduction due to an adverse reaction occurred in 9% of patients who received TAZVERIK.
The most common adverse reactions (≥20%) were fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, and abdominal pain.
Table 6 presents adverse reactions in patients with relapsed or refractory follicular lymphoma in Cohorts 4 and 5 of Study E7438-G000-101.
Table 6: Adverse Reactions (≥10%) in Patients with Relapsed or Refractory Follicular Lymphoma Who Received TAZVERIK in Cohorts 4 and 5 of Study E7438-G000-101
| Adverse Reaction | TAZVERIK N=99 |
|
| All Grades (%) | Grade 3 or 4 (%) | |
| General | ||
| Fatiguea | 36 | 5 |
| Pyrexia | 10 | 0 |
| Infections | ||
| Upper respiratory tract infectionb | 30 | 0 |
| Lower respiratory tract infectionc | 17 | 0 |
| Urinary tract infectiond | 11 | 2 |
| Gastrointestinal | ||
| Nausea | 24 | 1 |
| Abdominal paine | 20 | 3 |
| Diarrhea | 18 | 0 |
| Vomiting | 12 | 1 |
| Musculoskeletal and connective tissue | ||
| Musculoskeletal painf | 22 | 1 |
| Skin and subcutaneous tissue | ||
| Alopecia | 17 | 0 |
| Rashg | 15 | 0 |
| Respiratory and mediastinal system | ||
| Coughh | 17 | 0 |
| Nervous system | ||
| Headachei | 13 | 0 |
| aIncludes fatigue and asthenia bIncludes laryngitis, nasopharyngitis, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, viral upper respiratory tract infection cIncludes bronchitis, lower respiratory tract infection, tracheobronchitis dIncludes cystitis, urinary tract infection, urinary tract infection staphylococcal eIncludes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper fIncludes back pain, limb discomfort, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, myalgia, neck pain, non-cardiac chest pain, pain in extremity, pain in jaw, spinal pain gIncludes erythema, rash, rash erythematous, rash generalized, rash maculo-papular, rash pruritic, rash pustular, skin exfoliation hIncludes cough and productive cough iIncludes headache, migraine, sinus headache |
||
Clinically relevant adverse reactions occurring in <10% of patients who received TAZVERIK included:
Table 7 summarizes select laboratory abnormalities in patients with follicular lymphoma in Cohorts 4 and 5 of Study E7438-G000-101.
Table 7: Select Laboratory Abnormalities (≥10%) Worsening from Baseline in Patients with Relapsed or Refractory Follicular Lymphoma Who Received TAZVERIK in Cohorts 4 and 5 of Study E7438-G000-101
| Laboratory Abnormality | TAZVERIK* | |
| All Grades (%) | Grade 3 or 4 (%) | |
| Hematology | ||
| Decreased lymphocytes | 57 | 18 |
| Decreased hemoglobin | 50 | 8 |
| Decreased platelets | 50 | 7 |
| Decreased white blood cells | 41 | 9 |
| Decreased neutrophils | 20 | 7 |
| Chemistry | ||
| Increased glucose | 53 | 10 |
| Increased aspartate aminotransferase | 24 | 0 |
| Increased alanine aminotransferase | 21 | 2.3 |
| Increased alkaline phosphatase | 18 | 1.0 |
| Increased creatinine | 17 | 0 |
| *The denominator used to calculate the rate varied from 88 to 96 based on the number of patients with a baseline value and at least one post-treatment value. | ||
Coadministration of TAZVERIK with a strong or moderate CYP3A inhibitor increases tazemetostat plasma concentrations [see CLINICAL PHARMACOLOGY], which may increase the frequency or severity of adverse reactions. Avoid coadministration of strong or moderate CYP3A inhibitors with TAZVERIK. If coadministration of strong or moderate CYP3A inhibitors cannot be avoided, reduce TAZVERIK dose [see DOSAGE AND ADMINISTRATION].
Coadministration of TAZVERIK with a strong CYP3A inducer decreases tazemetostat plasma concentrations [see CLINICAL PHARMACOLOGY], and coadministration of TAZVERIK with a moderate CYP3A inducer may also decrease tazemetostat plasma concentrations. The decrease in tazemetostat plasma concentration may decrease the efficacy of TAZVERIK. Avoid coadministration of moderate or strong CYP3A inducers with TAZVERIK.
Coadministration of TAZVERIK with CYP3A substrates, including hormonal contraceptives, can result in decreased concentrations and reduced efficacy of CYP3A substrates [see Use In Specific Populations, CLINICAL PHARMACOLOGY].
Included as part of the PRECAUTIONS section.
The risk of developing secondary malignancies is increased following treatment with TAZVERIK. Across clinical trials of 758 adults who received TAZVERIK 800 mg twice daily as monotherapy, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or B-cell acute lymphoblastic leukemia (B-ALL) occurred in 1.7% of patients. One pediatric patient developed T-cell lymphoblastic lymphoma (T-LBL). Monitor patients long-term for the development of secondary malignancies.
Based on findings from animal studies and its mechanism of action, TAZVERIK can cause fetal harm when administered to pregnant women. There are no available data on TAZVERIK use in pregnant women to inform the drug-associated risk. Administration of tazemetostat to pregnant rats and rabbits during organogenesis resulted in dose-dependent increases in skeletal developmental abnormalities in both species beginning at maternal exposures approximately 1.5 times the adult human exposure (area under the plasma concentration time curve [AUC0-45h]) at the 800 mg twice daily dose.
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAZVERIK and for 6 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with TAZVERIK and for 3 months after the final dose [see Use In Specific Populations].
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Advise patients of the increased risk of secondary hematologic malignancies. Advise patients to inform their healthcare provider if they experience fatigue, easy bruising, fever, bone pain, or paleness [see WARNINGS AND PRECAUTIONS].
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Use In Specific Populations].
Advise females of reproductive potential to use effective non-hormonal contraception during treatment with TAZVERIK and for 6 months after the final dose [see Use In Specific Populations].
Advise males with female partners of reproductive potential to use effective contraception during treatment with TAZVERIK and for 3 months after the final dose [see Use In Specific Populations, Nonclinical Toxicology].
Advise women not to breastfeed during treatment with TAZVERIK and for 1 week after the final dose [see Use In Special Populations].
Advise patients and caregivers to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products. Inform patients to avoid St. John’s wort, grapefruit, and grapefruit juice while taking TAZVERIK [see DRUG INTERACTIONS].
Dedicated carcinogenicity studies were not conducted with tazemetostat, but T-LBL, MDS, AML, and B-ALL have been reported clinically and T-LBL occurred in juvenile and adult rats after ~9 or more weeks of tazemetostat administration during 13-week toxicity studies. Based on nonclinical studies in rats, the risk of TÂLBL appears to be greater with longer duration dosing.
Tazemetostat did not cause genetic damage in a standard battery of studies including a screening and pivotal bacterial reverse mutation (Ames) assay, an in vitro micronucleus assessment in human peripheral blood lymphocytes, and an in vivo micronucleus assessment in rats after oral administration.
Fertility and early embryonic development studies have not been conducted with tazemetostat; however, assessments of male and female reproductive organs were included in 4-and 13-week repeat-dose toxicity studies in rats and cynomolgus monkeys. Oral daily administration of tazemetostat did not result in any notable effects in the adult male and female reproductive organs [see Use In Specific Populations].
Based on findings from animal studies and its mechanism of action [see CLINICAL PHARMACOLOGY], TAZVERIK can cause fetal harm when administered to pregnant women. There are no available data on TAZVERIK use in pregnant women to inform the drug-associated risk. Administration of tazemetostat to pregnant rats and rabbits during organogenesis resulted in dose-dependent increases in skeletal developmental abnormalities in both species beginning at maternal exposures approximately 1.5 times the adult human exposure [AUC0-45h] at the 800 mg twice daily dose (see Data). Advise pregnant women of the potential risk to a fetus.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Animal Data
In pregnant rats, once daily oral administration of tazemetostat during the period of organogenesis from gestation day (GD) 7 through 17 resulted in no maternal adverse effects at doses up to 100 mg/kg/day (approximately 6 times the adult human exposure at 800 mg twice daily). Skeletal malformations and variations occurred in fetuses at doses of ≥50 mg/kg (approximately 2 times the adult human exposure at the 800 mg twice daily dose). At 200 mg/kg (approximately 14 times the adult human exposure at the 800 mg twice daily dose), major findings included increased post implantation loss, missing digits, fused vertebrae, domed heads and fused bones of the skull, and reduced fetal body weights.
In pregnant rabbits, no adverse maternal effects were observed after once daily oral administration of 400 mg/kg/day tazemetostat (approximately 7 times the adult human exposure at the 800 mg twice daily dose) from GD 7 through 19. Skeletal variations were present at doses ≥100 mg/kg/day (approximately 1.5 times the adult human exposure at the 800 mg twice daily dose), with skeletal malformations at ≥200 mg/kg/day (approximately 5.6 times the adult human exposure at the 800 mg twice daily dose). At 400 mg/kg (approximately 7 times the adult human exposure at the 800 mg twice daily dose), major findings included increased post implantation loss and cleft palate and snout.
There are no animal or human data on the presence of tazemetostat in human milk or on its effects on the breastfed child or milk production. Because of the potential risk for serious adverse reactions from TAZVERIK in the breastfed child, advise women not to breastfeed during treatment with TAZVERIK and for one week after the final dose.
Verify the pregnancy status of females of reproductive potential prior to initiating TAZVERIK [see Use In Specific Populations].
TAZVERIK can cause fetal harm when administered to pregnant women [see Use In Specific Populations].
Females
Advise females of reproductive potential to use effective non-hormonal contraception during treatment with TAZVERIK and for 6 months after the final dose. TAZVERIK can render some hormonal contraceptives ineffective [see DRUG INTERACTIONS].
Males
Advise males with female partners of reproductive potential to use effective contraception during treatment with TAZVERIK and for at least 3 months after the final dose.
The safety and effectiveness of TAZVERIK have been established in pediatric patients aged 16 years and older (adolescents) with metastatic or locally advanced epithelioid sarcoma. Use of TAZVERIK for this indication is supported by evidence from adequate and well-controlled studies in adults (including 3 adolescent patients aged 16 years) [see ADVERSE REACTIONS, CLINICAL PHARMACOLOGY, Clinical Studies].
The safety and effectiveness of TAZVERIK in pediatric patients aged less than 16 years have not been established.
In a 13-week juvenile rat toxicology study, animals were dosed daily from post-natal day 7 to day 97 (approximately equivalent to neonate to adulthood). Tazemetostat resulted in:
Clinical studies of TAZVERIK did not include sufficient numbers of patients with epithelioid sarcoma or relapsed or refractory follicular lymphoma aged 65 and over to determine whether they respond differently from younger subjects.
No dose adjustment of TAZVERIK is recommended for patients with mild to severe renal impairment or end stage renal disease [see CLINICAL PHARMACOLOGY].
No dose adjustment of TAZVERIK is recommended for patients with mild hepatic impairment (total bilirubin > 1 to 1.5 times upper limit of normal [ULN] or AST > ULN). TAZVERIK has not been studied in patients with moderate (total bilirubin > 1.5 to 3 times ULN) or severe (total bilirubin > 3 times ULN) hepatic impairment [see CLINICAL PHARMACOLOGY].
No Information Provided
None.
Tazemetostat is an inhibitor of the methyltransferase, EZH2, and some EZH2 gain-of-function mutations including Y646X, A682G, and A692V. Tazemetostat also inhibited EZH1 with a half-maximal inhibitory concentration (IC50) of 392 nM, approximately 36 times higher than the IC50 for inhibition of EZH2.
The most well-characterized function of EZH2 is as the catalytic subunit of the polycomb repressive complex 2 (PRC2), catalyzing mono-, di-, and trimethylation of lysine 27 of histone H3. Trimethylation of histone H3 leads to transcriptional repression.
SWItch/Sucrose Non-Fermentable (SWI/SNF) complexes can antagonize PRC2 function in the regulation of the expression of certain genes of patients with epithelioid sarcoma. Preclinical in vitro and in vivo models with the loss or dysfunction of certain SWI/SNF complex members (e.g., integrase interactor 1 [INI1/SNF5/SMARCB1/BAF47], SMARCA4, and SMARCA2) can lead to aberrant EZH2 activity or expression and a resulting oncogenic dependence on EZH2.
Tazemetostat suppressed proliferation of B-cell lymphoma cell lines in vitro and demonstrated antitumor activity in a mouse xenograft model of B-cell lymphoma with or without EZH2 gain-of-function mutations. Tazemetostat demonstrated greater effects on the inhibition of proliferation of lymphoma cell lines with mutant EZH2.
Tazemetostat exposure-response relationships and the time course of pharmacodynamic responses are unknown.
The effect of orally administered TAZVERIK, at doses ranging from 100 mg to 1600 mg twice daily (0.125 to 2 times the approved recommended dosage) for 15 days, on the heart-rate corrected QT (QTc) interval was evaluated in a dose-finding study in 38 patients with advanced malignancies. Tazemetostat and its metabolite EPZ-6930 did not cause a large mean increase (i.e. >20 ms) on the QTc interval at the 800 mg twice daily dose.
The largest mean increase (upper bound of 90% confidence interval) in QTc were 6.1 ms (8.5 ms) and 9.3 ms (12.5 ms) at a dose of 800 mg twice daily and 1600 mg twice daily, respectively.
The systemic exposure of tazemetostat is approximately dose proportional over the dose range of 200 mg to 1600 mg twice daily of TAZVERIK (0.25 to 2 times the approved recommended dosage). Following TAZVERIK 800 mg orally twice daily, steady-state was reached by Day 15. The mean (coefficient of variation [CV]%) steady-state peak plasma concentration (Cmax) was 829 (56%) ng/mL and AUC0-12h was 3340 (49%) ng•h/mL. Tazemetostat exhibited time-dependent pharmacokinetics (PK). The mean accumulation ratio (measured by AUC) was 0.58.
The mean absolute oral bioavailability of tazemetostat is approximately 33%. The median time to reach the peak plasma concentration of tazemetostat is 1 to 2 hours.
Effect Of Food
A high-fat, high-calorie (approximately 800 to 1000 calories) meal does not have a significant effect on tazemetostat exposure.
The mean (CV%) apparent volume of distribution at steady-state (Vss/F) is 1230 L (46%). Tazemetostat is 88% bound to human plasma proteins in vitro. The blood-to-plasma ratio is 0.73.
At steady-state, the estimated mean (CV%) terminal elimination half-life of tazemetostat is 3.1 hours (14%) and the apparent total clearance (CLss/F) is 274 L/h (49%).
Metabolism
In vitro, tazemetostat is metabolized by CYP3A to form the inactive major metabolites M5 (EPZ-6930) and M3 (EPZ006931). M5 undergoes further metabolism by CYP3A.
Excretion
Following a single oral dose of radiolabeled tazemetostat, 94% of the total radioactivity was recovered over 12 days, with 15% excreted into urine and 79% into feces.
Age (16 to 91 years), sex, race (White, Black, Asian), body weight (37.3 to 173 kg), mild hepatic impairment (total bilirubin > 1 to 1.5 times ULN or AST > ULN) and renal impairment, including end stage renal disease, have no clinically meaningful effect on the pharmacokinetics of tazemetostat. The effect of moderate to severe hepatic impairment has not been studied.
Effect Of CYP3A Inhibitors On Tazemetostat
Coadministration of fluconazole (a moderate CYP3A inhibitor) with TAZVERIK 400 mg twice daily in patients increased tazemetostat steady-state AUC0-8h by 3.1-fold and Cmax by 2.3-fold.
Coadministration of itraconazole (a strong CYP3A inhibitor) with TAZVERIK 400 mg twice daily in patients increased tazemetostat steady-state AUC0-12h by 2.5-fold and Cmax by 1.9-fold.
Effect Of CYP3A Inducers On Tazemetostat
Coadministration of rifampin (a strong CYP3A inducer) with TAZVERIK 800 mg twice daily in patients decreased tazemetostat steady-state AUC0-12h by 84% and Cmax by 84%. Coadministration of tazemetostat with a moderate CYP3A inducer is also predicted to decrease tazemetostat plasma concentrations, which may decrease the efficacy of tazemetostat.
Effect Of Gastric Acid Reducing Agents On Tazemetostat
Coadministration of omeprazole (a proton pump inhibitor) with TAZVERIK 800 mg twice daily in patients increased tazemetostat steady-state AUC0-8h by 26% and Cmax by 25%, which is not expected to have clinically relevant impact.
Effect Of Tazemetostat On CYP3A Substrate
Coadministration of TAZVERIK 800 mg twice daily with oral midazolam (a sensitive CYP3A substrate) in patients decreased midazolam AUC0-12h by 40% and Cmax by 21%.
Effect Of Tazemetostat On CYP2C8 And CYP2C19 Substrates
Coadministration of TAZVERIK 800 mg twice daily with repaglinide (a sensitive CYP2C8 substrate) and omeprazole (a sensitive CYP2C19 substrate) in patients increased repaglinide AUC0-8h by 80% and Cmax by 51%; and had no effect on the exposure of omeprazole.
Metabolic Enzymes
Tazemetostat does not inhibit CYP1A2, CYP2B6, CYP2C9, and CYP2D6 at clinically relevant concentrations.
Drug Transporters
Tazemetostat is a substrate of p-glycoprotein (P-gp). Tazemetostat is not a substrate of breast cancer resistance protein (BCRP); renal transporters organic cation transporter 2 (OCT2), organic anion transporter 3 (OAT3), and multidrug and toxin extrusion transporter 1 (MATE1); or hepatic transporters organic anion transporting polypeptide 1B1 (OATP1B1) and organic anion transporting polypeptide 1B3 (OATP1B3).
Tazemetostat is an inhibitor of MATE1 and multidrug and toxin extrusion transporter 2-K (MATE2-K). Tazemetostat does not inhibit P-gp, BCRP, OATP1B1, OATP1B3, organic cation transporter 1 (OCT1), OCT2, organic anion transporter 1 (OAT1), OAT3, or bile salt export pump (BSEP) at clinically relevant concentrations.
The efficacy of TAZVERIK was evaluated in an open-label, single-arm cohort (Cohort 5) of a multi-center study (Study EZH-202, NCT02601950) in patients with histologically confirmed, metastatic or locally advanced epithelioid sarcoma. Patients were required to have INI1 loss, detected using local tests, and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2. Patients received TAZVERIK 800 mg orally twice daily until disease progression or unacceptable toxicity. Tumor response assessments were performed every 8 weeks. The major efficacy outcome measures were confirmed overall response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR) and duration of response (DOR). Median duration of follow-up was 14 months (range 0.4 to 31).
Among the 62 patients who received TAZVERIK, median age was 34 years (range 16 to 79); 63% were male, 76% were White, 11% were Asian, 44% had proximal disease, 92% had an ECOG PS of 0 or 1, and 8% had an ECOG PS of 2. Prior surgery occurred in 77% of patients; 61% received prior systemic chemotherapy.
Efficacy results are summarized in Table 8.
Table 8: Efficacy Results for Patients with Epithelioid Sarcoma Enrolled in Cohort 5 of Study EZH-202
| Efficacy Endpoints | TAZVERIK N=62 |
| Overall Response Rate (95% CI)* | 15% (7%, 26%) |
| Complete Response | 1.6% |
| Partial Response | 13% |
| Duration of Response | |
| % with duration ≥ 6 months | 67% |
| Range in months | 3.7, 24.5+ |
| CI = Confidence Interval *Time to response ranged from 1.4 to 18.4 months. |
|
The efficacy of TAZVERIK was evaluated in two open-label, single-arm cohorts (Cohorts 4 and 5) of a multi-center study (Study E7438-G000-101, NCT01897571) in patients with histologically confirmed follicular lymphoma after at least 2 prior systemic therapies. Patients were required to have ECOG PS of 0-2 and were enrolled based on EZH2 mutation status. EZH2 mutations were identified prospectively using formalin-fixed, paraffin-embedded tumor samples, which were centrally tested using the cobas® EZH2 Mutation Test; the cobas EZH2 Mutation test is designed to detect the following mutations: Y646X [S,H,C], Y646F, Y646N, A682G, and A692V. Patients received TAZVERIK 800 mg orally twice daily until confirmed disease progression or unacceptable toxicity. Tumor response assessments were performed every 8 weeks through Week 24 and then every 12 weeks. The major efficacy outcome measures were ORR and DOR according to the International Working Group Non-Hodgkin Lymphoma (IWG-NHL) criteria1 as assessed by Independent Review Committee. Median duration of follow-up was 22 months (range 3 months to 44 months) for patients with EZH2 MT positive tumors and 36 months (range 32 months to 39 months) for patients whose tumors did not have an EZH2 mutation detected.
A total of 99 patients were enrolled, including 45 patients whose tumors had one of these EZH2 mutations (mutant) and 54 patients whose tumors did not have one of these mutations (wild-type).
Among the 45 patients with EZH2 mutant follicular lymphoma, median age was 62 years (range 38 to 80), 58% were female, 42% had early progression following front-line therapy (POD24), and all had an ECOG PS of 0 or 1. Race was reported in 84% of patients; of these patients, 82% were White. Based on the cobas EZH2 Mutation test, 36%, 29%, 27%, 11% and 2% of patients had the following mutations: Y646X [S,H,C], Y646F, Y646N, A682G, and A692V, respectively. The median number of lines of prior systemic therapy was 2 (range 1 to 11), with 49% refractory to rituximab, 49% refractory to their last therapy, and 9% had received prior stem cell transplant.
Among the 54 patients with EZH2 wild-type follicular lymphoma, median age was 61 years (range 36 to 87), 63% were male, 59% had POD24, and 91% had an ECOG PS of 0 or 1. Race was reported in 57% of patients; of these patients, 48% were White and 3% were Asian. The median number of lines of prior systemic therapy was 3 (range 1 to 8), with 59% refractory to rituximab, 41% refractory to their last therapy, and 39% had received prior stem cell transplant.
The approval of TAZVERIK was based upon the efficacy in 95 patients (42 EZH2 Mutant, 53 EZH2 Wild-Type) who had received at least 2 prior systemic therapies and is presented in Table 9.
Table 9: Efficacy Results for Patients with Relapsed or Refractory Follicular Lymphoma Enrolled into Cohorts 4 and 5 of Study E7438-G000-101
| Efficacy Endpoints | TAZVERIK N=95 |
|
| EZH2 Mutant Follicular Lymphoma N=42 |
EZH2 Wild-Type Follicular Lymphoma N=53 |
|
| Overall Response Rate (95% CI)* | 69% (53%, 82%) | 34% (22%, 48%) |
| Complete Response | 12% | 4% |
| Partial Response | 57% | 30% |
| Duration of Response | ||
| Median (95% CI) in months | 10.9 (7.2, NE) | 13.0 (5.6, NE) |
| Range in months | 0.0+, 22.1+ | 1, 22.5+ |
| CI = Confidence Interval; NE = Not Estimable. *Median time to response for patients with EZH2 MT follicular lymphoma was 3.7 months (range 1.6 to 10.9) and for patients with EZH2 WT follicular lymphoma was 3.9 months (range 1.6 to 16.3). |
||
REFERENCES
1Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. Â 2007;25(5):579-586.
No information provided. Please refer to the WARNINGS AND PRECAUTIONS section.
